SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001072613-22-000460
Filing Date
2022-06-17
Accepted
2022-06-17 17:10:34
Documents
1
Group Members
ALI BEHBAHANIANTHONY A. FLORENCE, JR.CARMEN CHANGFOREST BASKETTMOHAMAD H. MAKHZOUMINEA 16 GP, LLCNEA PARTNERS 16, L.P.NEW ENTERPRISE ASSOCIATES 16, L.P.PAUL WALKERPETER W. SONSINISCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 GROWTH EQUITY OPPORTUNITIES FUND V, LLC - CTI BIOPHARMA CORP. SCHEDULE 13D/A(#3) cti-geo5_18625.htm SC 13D/A 436132
  Complete submission text file 0001072613-22-000460.txt   438139
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Subject) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-48459 | Film No.: 221024948
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities V, LLC (Filed by) CIK: 0001706444 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A